Concerning the proficient MMR (pMMR)/microsatellite stable (MSS) population, which accounts for more than 90% of cases, the underlying rationale is that the induction of ICD by oxaliplatin combined with the ability of bevacizumab to restore adaptive immune mechanisms, normally downregulated by vascular endothelial growth factor (VEGF), could amplify T-cell-mediated cancer cell killing caused by ICIs. This evidence concerns the gene VEGFA and cancer.